ArticleBMC infectious diseases2025
Epidemiology, resistance profiles, and risk factors of multidrug- and carbapenem-resistant Serratia marcescens infections: a retrospective study of 242 cases.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Molecular Epidemiology of Carbapenem-ResistantInfection and drug resistance · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSerratia marcescens is an opportunistic pathogen increasingly associated with healthcare-associated infections and rising antimicrobial resistance. The emergence of multidrug-resistant (MDR) and carbapenem-resistant S. marcescens (CRSM) presents significant therapeutic challenges. However, data on the clinical and microbiological analyses of these infections remain limited.
methodsThis retrospective study included 242 hospitalized patients with S. marcescens infections admitted to Nanjing Drum Tower Hospital, China, from January 2012 to December 2020. Clinical characteristics, antimicrobial susceptibility profiles, and resistance patterns were analyzed. Patients were categorized based on infection site (urinary tract infection [UTI] vs. bloodstream infection [BSI]) and resistance phenotype (MDR and CRSM). Antimicrobial susceptibility testing (AST) was performed according to CLSI 2024 guidelines. Univariate and multivariate logistic regression analyses were conducted to identify independent risk factors associated with BSI, UTI, and CRSM.
resultsMDR isolates exhibited significantly lower susceptibility to β-lactams, aminoglycosides, and fluoroquinolones compared to non-MDR isolates, although amikacin and sulfamethoxazole retained moderate activity. Isolates from blood samples showed higher susceptibility to most antibiotics than urinary isolates, particularly imipenem (23.5% vs. 3.2%). Multivariate analysis identified prior hospitalization as an independent risk factor for S. marcescens BSI (OR = 2.8, P = 0.048), while kidney disease (OR = 4.2, P < 0.001) was independently associated with UTIs. Pulmonary infection (OR = 3.2, P = 0.020) and prior exposure to ≥ 3 antibiotic classes (OR = 3.7, P = 0.031) were independent predictors of carbapenem-resistant infections. Patients with MDR bacteremia had a markedly higher 28-day mortality (50.0%) than non-MDR cases (12.0%). The 28-day mortality rate for CRSM infections was 28.6%.
conclusionThis study reveals substantial differences in antimicrobial susceptibility between MDR and non-MDR S. marcescens isolates and highlights amikacin and sulfamethoxazole as potential treatment options against MDR strains. Didentified clinical risk factors-including prior hospitalization, kidney disease, and extensive antibiotic exposure-underscore the importance of early risk stratification and optimized antibiotic stewardship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.